NATICK, Mass., May 4 -- Boston Scientific Corporation (NYSE: BSX - News) today announced preliminary information related to U.S. sales of its TAXUS™ Express2™ paclitaxel-eluting coronary stent systems for the month of April.
Preliminary net U.S. sales of TAXUS systems for the month (22 selling days) were approximately $163 million. The Company said it was shipping to approximately 1,144 accounts at the end of the month. Preliminary net worldwide sales of TAXUS systems for the month were approximately $205 million. Total preliminary net sales for April were approximately $495 million.
The Company estimates its share of the U.S. drug-eluting stent market -- as of April 30th -- to be in excess of 70 percent, on a reorder basis.
The Company estimates the adoption rate for drug-eluting stents in the United States -- as of April 30th -- to be approximately 70 percent. The adoption rate represents the number of drug-eluting stents placed as a percentage of total stents placed.
"The TAXUS launch continues to go extremely well, with sales growing and execution remaining strong," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "More broadly, April was the first full month of TAXUS sales, which helped drive us to nearly $500 million in total sales for the month, an annualized run rate of approximately $6 billion. We are exceeding expectations not only with TAXUS, but across the organization."
The information in this news release is being provided to ensure fair disclosure to all investors in accordance with the Fair Disclosure regulations of the U.S. Securities and Exchange Commission. The Company plans to provide similar information periodically in the coming months.
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
This press release contains forward-looking statements. The Company wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and introduction, clinical trials, regulatory approvals, competitive offerings, intellectual property, litigation, the Company's overall business strategy, and other factors described in the Company's filings with the Securities and Exchange Commission.
| Contacts |
|
Milan Kofol (508-650-8569)
Investor Relations
Boston Scientific Corporation |
Paul Donovan (508-650-8541)
Media Relations
Boston Scientific Corporation
|
|